$QTTB News
Last published 19h ago
- 19h agoQTTBQ32 Bio to Participate in the 2026 Jefferies Global Healthcare Conference in LondonPR NewswireQ32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical-stage biotechnology company focused on developing innovative therapies for alopecia areata...
- 1w agoQTTBQ32 Bio Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1mo agoQTTBQ32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026PR NewswireQ32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical-stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") ...
- 1mo agoQTTBQ32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026PR NewswireQ32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical-stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") ...
- 1mo agoQTTBQ32 Bio - 1773829 - Q32 BIO INCEarnings Call TranscriptsWelcome, everyone, to this session of the Morgan Stanley Global Healthcare Conference. I'm Judah Fulmer, one of the SMIT biotech analysts here. We're very excited to have Lee and Sheila from Q32 representing the company.
- 1mo agoQTTBQ32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development OfficerPR NewswireQ32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical-stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") ...
- 2mo agoQTTBQ32 Bio to Participate in Upcoming September Investor ConferencesPR NewswireQ32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") ...
- 3mo agoQTTBQ32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate UpdatePR NewswireQ32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") ...
- 4mo agoQTTBQ32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded WarrantsPR NewswireQ32 Bio Inc. (Nasdaq: QTTB), ("Q32 Bio") a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and...
- 4mo agoQTTBQ32 Bio Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsPR NewswireQ32 Bio Inc. (Nasdaq: QTTB), ("Q32 Bio") a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") ...
- 4mo agoQTTBQ32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia AreataPR NewswireQ32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") ...
- 4mo agoQTTBQ32 Bio to Report 36-Week Topline Results from Part B of SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata on July 13, 2026PR NewswireQ32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") ...
- 5mo agoQTTBQ32 Bio Announces $55 Million Private Placement FinancingPR NewswireQ32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio" or "Company"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia...
- 6mo agoQTTBQ32 Bio Reports First Quarter 2026 Financial Results and Provides Corporate UpdatePR NewswireQ32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA)...
- 7mo agoQTTBQ32 Bio to Participate in the 25th Annual Needham Virtual Healthcare ConferencePR NewswireQ32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA)...
- 8mo agoQTTBQ32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate UpdatePR NewswireQ32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA)...
- 8mo agoABBVQTTBHCWBNKTR+3Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsightPR NewswireRecently published Alopecia Areata Market Insights report includes a comprehensive understanding of current treatment practices, alopecia areata...
- 8mo agoQTTBQ32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences ConferencePR NewswireQ32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA)...
- 8mo agoQTTBQ32 Bio Announces $10.5 Million Registered Direct OfferingPR NewswireQ32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA)...
- 11mo agoAKBAQTTBAkebia Announces Establishment of Rare Kidney Disease PipelineGlobeNewswireAcquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio Phase 2 basket trial planned to evaluate complement inhibitor in multiple rare kidney disease indications Phase 2
- 11mo agoQTTBAKBAQ32 Bio Sells Complement Inhibitor ADX-097PR NewswireQ32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA)...
- 12mo agoQTTBQ32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate UpdatePR NewswireQ32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA)...
- 1y agoQTTBQ32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia AreataPR NewswireQ32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA)...
- 1y agoQTTBQ32 Bio to Participate in the 2025 Wells Fargo Healthcare ConferencePR NewswireQ32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA)...
- 1y agoQTTBQ32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate UpdatePR NewswireQ32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA)...
- 1y agoQTTBQ32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical OfficerPR NewswireQ32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and...
- 1y agoQTTBQ32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate UpdatePR NewswireQ32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and...
- 1y agoQTTBQ32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia AreataPR NewswireQ32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA)...
- 1y agoQTTBQ32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia AreataPR NewswireQ32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio" or the "Company"), a clinical stage biotechnology company focused on developing innovative therapies for...
- 1y agoQTTBQ32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate UpdatePR NewswireQ32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune...
- 1y agoQTTBQ32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology MeetingPR NewswireQ32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune...
- 1y agoQTTBQ32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual MeetingPR NewswireQ32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune...
- 1y agoQTTBQ32 Bio to Participate in Upcoming March Investor ConferencesPR NewswireQ32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune...
- 1y agoQTTBQ32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia AreataPR NewswireQ32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune...
- 1y agoQTTBQ32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences ConferencePR NewswireQ32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune...
- 1y agoQTTBQ32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development ProgramPR NewswireQ32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune...
- 2y agoQTTBQ32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate UpdatePR NewswireQ32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune...
- 2y agoQTTBQ32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation ConferencePR NewswireQ32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune...
- 2y agoQTTBQ32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024PR NewswireQ32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune...
- 2y agoQTTBQ32 Bio to Participate in Upcoming September Investor ConferencesPR NewswireQ32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune...
- 2y agoQTTBQ32 Bio Reports Second Quarter 2024 Financial Results and Provides Corporate UpdatePR NewswireQ32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune...
- 2y agoQTTBQ32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic DermatitisPR NewswireQ32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune...
- 2y agoQTTBQ32 Bio Joins Russell 3000® IndexPR NewswireQ32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune...
- 2y agoQTTBQ32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate UpdatePR NewswireQ32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune...
- 2y agoQTTBQ32 Bio Appoints Lee Kalowski as President & Chief Financial OfficerPR NewswireQ32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune...
- 2y agoQTTBQ32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 MillionPR NewswireQ32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune...